A dendritic cell vaccine was safe and induced immune responses in patients with multiple myeloma
Bottom Line: A dendritic cell vaccine administered before and after autologous stem cell transplant (ASCT) was safe and immunogenic and was associated with durable clinical responses in patients with high-risk multiple myeloma.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR)
Authors: Frederick L. Locke, MD, chair of the Blood and Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, was the senior author of the study.
Background: “Multiple ...












